In the last a long time, the quantity of patients referred for allogeneic hematopoietic cell transplantation has dropped considerably,133 even so the procedure need to be advised to younger/suit patients in whom BCR/BCL2 inhibitor treatment method fails, especially in People with TP53translocations or amplifications on top of the genomic alteration